LB-P8 not checked

LISCure Biosciences

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Primary Sclerosing Cholangitis (PSC)
Main trialPhase 2
“The study is designed to assess the safety and efficacy of LB-P8 in patients with primary sclerosing cholangitis.”In the company’s words, NCT06699121 on ClinicalTrials.gov

Other drugs for Primary Sclerosing Cholangitis (PSC)

All 7 drugs for Primary Sclerosing Cholangitis (PSC)

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Recruiting Mar 2028 A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC
Phase 1Completed 1 Apr 2022 A Study to Assess the Safety and Tolerability of LB-P6 and LB-P8 in Healthy Participants
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow LB-P8

Following is part of Solo: you see every change to LB-P8 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in